Pubblicato in data September 22, 2017

A field with a national market of 10 billion Euro, characterised by continuous innovation and positive outcomes on health and quality of life. The Italian medical devices industry chooses the Verona Fair to present itself on a national level. On the 23 and 24 January in fact, the first edition of Innovabiomed is scheduled. The event is organized by Veronafiere Spa together with the Mirandola district – considered the “Italian Biomedical Silicon Valley” – and RPM Media Srl Group. The new format includes two days of meeting and comparison between suppliers and manufacturers in the field of medical devices that may be applied in many different clinical areas ranging from surgery to oncology, from hemodialysis to anesthesia, from diagnostics to resuscitation. The common thread is always innovation, along the entire production chain: materials, technologies, components and services. However Innovabiomed also wishes to be a professional updating opportunity, outlining medium and long-term scenarios through conferences, technical seminars and thematic workshops.
“Innovabiomed becomes part of the more than 60 events that Veronafiere organizes every year in the world or in its own district” – said Maurizio Danese, president of Veronafiere–. Our industrial plan for 2020, among the various growth drivers, reserves € 23 million from a total of 94 for investments in the development of new trade fair products. The Innovabiomed start-up becomes part of this reality logic, representing a crucial industrial sector for its social value and that now easily finds in Verona a moment for promoting the business of its companies. “


In the Country there are 4.480 companies operating in the biomedical field, with 70 thousand employees. 69% of companies and 83% of turnover are concentrated in five regions: Lombardia, Emilia-Romagna, Lazio, Veneto and Tuscany (source 2016 Assobiomedica Report).


The Modena area with Mirandola is considered the first biomedical district in Europe and the second in the world, as explained by Alberto Nicolini, editor of the website “Mirandola has become one of the most important biomedical districts in the world because both the leading corporations in the industry and many small and medium-sized companies with very high levels of expertise are present. And Innovabiomed becomes the location that offers to aid, in a modern way, the choices that experience has proven to be winning: to innovate by sharing skills.”


The first edition of Innovabiomed was shown today at Verona. In addition to Maurizio Danese, president of Veronafiere and Alberto Nicolini, Giovanni Mantovani, general manager of Veronafiere, Federico Sboarina, mayor of Verona, Luca Coletto, Health councilor of the Veneto Region, Carlo Adami, vascular surgeon and creator of Innovabiomed , Giampaolo Tortora, oncologist and member of the Innovabiomed scientific committee, Gino Gerosa, cardio surgeon and member of the Innovabiomed scientific committee, and Marco Gibertoni, a biomedical field professional and Innovabiomed innovator, have spoken.


This new project is proof that technology and innovation are the instruments of economic growth for our territory,” said Mayor Sboarina. “It is important to note that Veronafiere’s design is aligned with the programme of this Administration. Transorming the Fair in Spa and diversifying its products are certainly the keys to staying ahead of the competition”.


Today, also Veneto, with 500 active companies, 6,800 employees and a turnover of over 2 billion euros, represents a hub of excellence in Italy, especially in the fields of biotechnology, diagnostics, dental, orthopedics and ophthalmology.


“The Hta-Health technology assessment – confirmed the regional councillor Coletto – has a significant turnover and downstream activities, but it is mainly used to increase the level of excellence of Veneto healthcare, which is based on innovation, teaching and research, without mentioning proper management of dedicated resources. All of this always with the goal of a better assistance and quality of life for the patients”.